BridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on BridgeBio Pharma yesterday and set a price target of $95.00.

Jason Zemansky has given his Buy rating due to a combination of factors that extend beyond BridgeBio Pharma’s recent clinical achievements, highlighting a clear strategy toward financial sustainability. He underscores management’s focus on managing operating expenses and strengthening the balance sheet, which supports the company’s stated path to profitability by 2027 and meaningful cash generation thereafter.

At the same time, he sees substantial upside remaining in the equity story, driven by continued growth of Attruby, higher potential forecasts for three upcoming product launches, and a broader pipeline that he believes is underappreciated by the market. Zemansky also argues that concerns around Pfizer’s tafamidis IP case are likely overstated for BridgeBio, as Attruby’s superior potency and clinical profile should support long-term commercial uptake and leave the overall risk/reward profile attractive at current levels.

In another report released today, Barclays also maintained a Buy rating on the stock with a $157.00 price target.